A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In enzymology, a retinal dehydrogenase, also known as retinaldehyde dehydrogenase (RALDH), catalyzes the chemical reaction converting retinal to retinoic acid. This enzyme belongs to the family of oxidoreductases, specifically the class acting on aldehyde or oxo- donor groups with nicotinamide adenine dinucleotide (NAD+) or nicotinamide adenine dinucleotide phosphate (NADP+) as acceptor groups, the systematic name being retinal:NAD+ oxidoreductase. This enzyme participates in retinol metabolism. The general scheme for the reaction catalyzed by this enzyme is:
The reign of the young Władysław III (1434–44), who succeeded his father Władysław II Jagiełło and ruled as king of Poland and Hungary, was cut short by his death at the Battle of Varna, during a crusade against the Ottoman Empire. This disaster led to an interregnum of three years that ended with the accession of Władysław's brother Casimir IV Jagiellon in 1447. Critical developments of the Jagiellonian period were concentrated during Casimir IV's long reign, which lasted until 1492. In 1454, Royal Prussia was incorporated by Poland and the Thirteen Years' War of 1454–66 with the Teutonic state ensued. In 1466, the milestone Peace of Thorn was concluded. This treaty divided Prussia to create East Prussia, the future Duchy of Prussia, a separate entity that functioned as a fief of Poland under the administration of the Teutonic Knights. Poland also confronted the Ottoman Empire and the Crimean Tatars in the south, and in the east helped Lithuania fight the Grand Duchy of Moscow. The country was developing as a feudal state, with a predominantly agricultural economy and an increasingly dominant landed nobility. Kraków, the royal capital, was turning into a major academic and cultural center, and in 1473 the first printing press began operating there. With the growing importance of szlachta (middle and lower nobility), the king's council evolved to become by 1493 a bicameral General Sejm (parliament) that no longer represented exclusively top dignitaries of the realm.
is the fact that unipolarity has not provoked a global alarm to restore a balance of power." The same anomaly stressed seventeen other experts on alliances, Stephen Walt, Randall Schweller, Xiaoyu Pu, John Ikenberry, Robert Pape, T. V. Paul, Jack S. Levy, William R. Thompson, John Lewis Gaddis, David A. Lake, Campbell Craig, Fareed Zakaria, John M. Owen, Michael Mastanduno, Thomas S. Mowle, David H. Sacko and Terry Narramore:
=== Development === The first human clinical trial using ex vivo dendritic cells transfected with mRNA encoding tumor antigens (therapeutic cancer mRNA vaccine) was started in 2001. Four years later, the successful use of modified nucleosides as a method to transport mRNA inside cells without setting off the body's defense system was reported. Clinical trial results of an mRNA vaccine directly injected into the body against cancer cells were reported in 2008. BioNTech in 2008, and Moderna in 2010, were founded to develop mRNA biotechnologies. The US research agency DARPA launched at this time the biotechnology research program ADEPT to develop emerging technologies for the US military. The agency recognized the potential of nucleic acid technology for defense against pandemics and began to invest in the field. DARPA grants were seen as a vote of confidence that in turn encouraged other government agencies and private investors to invest in mRNA technology. DARPA awarded at the time a $25 million grant to Moderna. The first human clinical trials using an mRNA vaccine against an infectious agent (rabies) began in 2013. Over the next few years, clinical trials of mRNA vaccines for a number of other viruses were started. mRNA vaccines for human use were studied for infectious agents such as influenza, Zika virus, cytomegalovirus, and Chikungunya virus.
Sources: en.wikipedia.org
The Industrial Revolution in Japan occurred during the Meiji era. The industrial revolution began around 1870 as Meiji era leaders decided to catch up with the West. The government built its first railroads, improved roads, and inaugurated a land reform program to prepare the country for further development. It inaugurated a new Western-based education system for all young people, sent thousands of students to the United States and Europe, and hired more than 3,000 Westerners to teach modern science, mathematics, technology, and foreign languages in Japan (O-yatoi gaikokujin). In 1871, a group of Japanese politicians known as the Iwakura Mission toured Europe and the US to learn western ways. The result was a deliberate state-led industrialization policy to enable Japan to quickly catch up. Japan developed modern industry through direct state intervention. Government-owned enterprises were important to the development of key economic sectors like railways. Through government connections, major private enterprises received various forms of financial support from the state. Modern industry first appeared in textiles, including cotton and especially silk, which was based in home workshops in rural areas. Due to the importing of new textile manufacturing technology from Europe, between 1886 and 1897, Japan's total value of yarn output rose from 12 million to 176 million yen. In 1886, 62% of yarn in Japan was imported; by 1902, most yarn was produced locally.
The life cycle of this insect has four stages: fertilized egg, larva, pupa, and adult. Embryogenesis in Drosophila has been extensively studied, as its small size, short generation time, and large brood size makes it ideal for genetic studies. It is also unique among model organisms in that cleavage occurs in a syncytium.
However Black Bank, which as of April 2015 captured 5% of the darknet market's listings, announced on May 18, 2015, its closure for "maintenance" before disappearing in a similar scam. Following these events commentators suggested that further market decentralization could be required, such as the service OpenBazaar, in order to protect buyers and vendors from this risk in the future as well as more widespread support from multisig cryptocurrency payments. In April, TheRealDeal, the first open cyber-arms market for software exploits as well as drugs, launched to the interest of computer security experts. In May, varied DDOS attacks were performed against different markets including TheRealDeal. The market owners set up a phishing website to get the attacker's password, and subsequently revealed collaboration between the attacker and the administrator of Mr Nice Guy's market who was also planning to scam his users. This information was revealed to news site DeepDotWeb. On July 31, the Italian police in conjunction with Europol shut down the Italian language Babylon darknet market seizing 11,254 Bitcoin wallet addresses and 1 million euros. At the end of August, the leading marketplace Agora announced its imminent temporary closure after reporting suspicious activity on their server, suspecting some kind of deanonymization bug in Tor. By October 2015, AlphaBay was recognized as the largest market.
Sources: en.wikipedia.org
The 2012 Colombian peace process refers to the dialogue in Havana, Cuba between the Colombian government and the FARC-EP to find a political solution to the armed conflict. After almost four years of peace negotiations, the Colombian state and the FARC announced consenus on a 6-point plan towards peace and reconciliation. The government also began a process of assistance and reparation for victims of the conflict. Recently, U.P. supporters reconstituted the political party within the reconciliation process. Colombia's congress approved the revised peace accord. In February 2015, the Historical Commission on the Conflict and its Victims (Comisión Histórica del Conflicto Armado y sus Víctimas – CHCV) published a report entitled "Contribution to an Understanding of the Armed Conflict in Colombia." The document addresses the "multiple reasons for the conflict, the principle factors and circumstances that made it possible, and the most notable impacts on the population", and explains Colombia's armed conflict in terms of international law.
Skin grafting, in more rudimentary forms, has been practiced since ancient times. The Ebers Papyrus of ancient Egypt contains a brief treatise on xenografting. Around 500 years later, members of the Hindu Kamma caste are described as performing skin grafts which included the usage of subcutaneous fat. The 2nd century AD Greek philosopher Celsus is also known to have developed a method to reconstruct the foreskins of Jewish men using skin grafts, as circumcision was considered barbaric in Greek and Roman society. More modern uses of skin grafting were described in the mid-to-late 19th century, including Reverdin's use of the pinch graft in 1869; Ollier's and Thiersch's uses of the split-thickness graft in 1872 and 1886, respectively; and Wolfe's and Krause's use of the full-thickness graft in 1875 and 1893, respectively. John Harvey Girdner demonstrated skin graft transplant from a deceased donor in 1880. Today, skin grafting is commonly used in dermatologic surgery. Recently Reverdin's technique is used but with very small wounds (less than 3 mm diameter). Such small wounds heal in a short time without scars. This technique is called SkinDot.
== Biological function == NADPH oxidases (NOXes) are one of the major sources of cellular reactive oxygen species (ROS), and they still are the focus of extensive research interest due to their exclusive function in producing ROS under normal physiological conditions. The NADPH oxidase complex is dormant under normal circumstances but is activated to assemble in the membranes during respiratory burst. The activated NADPH oxidase generates superoxide which has roles in animal immune response and plant signalling. Superoxide can be produced in phagosomes which have ingested bacteria and fungi, or it can be produced outside of the cell. In macrophages, superoxide kills bacteria and fungi by mechanisms that are not yet fully understood. Superoxide spontaneously dismutates to form peroxide which is then protonated to produce hydrogen peroxide. Opinions are polarised as to how the oxidase kills microbes in neutrophils. On the one hand it is thought that hydrogen peroxide acts as substrate for myeloperoxidase to produce hypochlorous acid. It may also inactivate critical metabolic enzymes, initiate lipid peroxidation, damage iron-sulphur clusters, and liberate redox-active iron, which allows the generation of indiscriminate oxidants such as the hydroxyl radical.
== Further reading == Johnson JE, Cornell RB (1999). "Amphitropic proteins: regulation by reversible membrane interactions (review)". Molecular Membrane Biology. 16 (3): 217–35. doi:10.1080/096876899294544. PMID 10503244. Alenghat FJ, Golan DE (2013). "Membrane protein dynamics and functional implications in mammalian cells". Current Topics in Membranes. 72: 89–120. doi:10.1016/b978-0-12-417027-8.00003-9. ISBN 9780124170278. PMC 4193470. PMID 24210428.{{cite journal}}: CS1 maint: periodical has ISBN (link)
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.